THER ADV INFECT DIS 润色咨询

Therapeutic Advances in Infectious Disease

出版年份：2013 年文章数：164 投稿命中率： 开通期刊会员，数据随心看

出版周期：annual 自引率：暂无数据 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2179050, encodeId=a42821e90503c, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：师兄成功发表了一篇，我了解了下，是本不错的期刊，近年来，表现也还不错，特别是在中国地区的收稿量有所增加，我也准备来投一篇，期望中啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf526407066, createdName=ms59932566, createdTime=Wed Jan 03 15:45:01 CST 2024, time=2024-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178706, encodeId=094221e87062d, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：对这个本期刊的印象不错，编辑团队经验很丰富，发表的论文质量都比较高，涉及的学科还比较广泛，这本期刊在首次获得影响因子时就超过了5分，学术影响力和潜力还是很大的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0af16407062, createdName=ms31231444, createdTime=Tue Jan 02 09:26:32 CST 2024, time=2024-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1127921, encodeId=2425112e92180, content=误差线怎么计算？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:59 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1127922, encodeId=1590112e92280, content=qPCR的结果如何处理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:59 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2024-01-03 ms59932566 来自上海

    审稿速度:3.0 | 投稿命中率:50.0
    经验分享：师兄成功发表了一篇，我了解了下，是本不错的期刊，近年来，表现也还不错，特别是在中国地区的收稿量有所增加，我也准备来投一篇，期望中啊

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2179050, encodeId=a42821e90503c, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：师兄成功发表了一篇，我了解了下，是本不错的期刊，近年来，表现也还不错，特别是在中国地区的收稿量有所增加，我也准备来投一篇，期望中啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf526407066, createdName=ms59932566, createdTime=Wed Jan 03 15:45:01 CST 2024, time=2024-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178706, encodeId=094221e87062d, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：对这个本期刊的印象不错，编辑团队经验很丰富，发表的论文质量都比较高，涉及的学科还比较广泛，这本期刊在首次获得影响因子时就超过了5分，学术影响力和潜力还是很大的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0af16407062, createdName=ms31231444, createdTime=Tue Jan 02 09:26:32 CST 2024, time=2024-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1127921, encodeId=2425112e92180, content=误差线怎么计算？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:59 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1127922, encodeId=1590112e92280, content=qPCR的结果如何处理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:59 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2024-01-02 ms31231444 来自上海

    审稿速度:6.0 | 投稿命中率:50.0
    经验分享：对这个本期刊的印象不错，编辑团队经验很丰富，发表的论文质量都比较高，涉及的学科还比较广泛，这本期刊在首次获得影响因子时就超过了5分，学术影响力和潜力还是很大的。

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2179050, encodeId=a42821e90503c, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：师兄成功发表了一篇，我了解了下，是本不错的期刊，近年来，表现也还不错，特别是在中国地区的收稿量有所增加，我也准备来投一篇，期望中啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf526407066, createdName=ms59932566, createdTime=Wed Jan 03 15:45:01 CST 2024, time=2024-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178706, encodeId=094221e87062d, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：对这个本期刊的印象不错，编辑团队经验很丰富，发表的论文质量都比较高，涉及的学科还比较广泛，这本期刊在首次获得影响因子时就超过了5分，学术影响力和潜力还是很大的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0af16407062, createdName=ms31231444, createdTime=Tue Jan 02 09:26:32 CST 2024, time=2024-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1127921, encodeId=2425112e92180, content=误差线怎么计算？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:59 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1127922, encodeId=1590112e92280, content=qPCR的结果如何处理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:59 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2021-12-28 MS68862005

    误差线怎么计算？

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2179050, encodeId=a42821e90503c, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享：师兄成功发表了一篇，我了解了下，是本不错的期刊，近年来，表现也还不错，特别是在中国地区的收稿量有所增加，我也准备来投一篇，期望中啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf526407066, createdName=ms59932566, createdTime=Wed Jan 03 15:45:01 CST 2024, time=2024-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2178706, encodeId=094221e87062d, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：对这个本期刊的印象不错，编辑团队经验很丰富，发表的论文质量都比较高，涉及的学科还比较广泛，这本期刊在首次获得影响因子时就超过了5分，学术影响力和潜力还是很大的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0af16407062, createdName=ms31231444, createdTime=Tue Jan 02 09:26:32 CST 2024, time=2024-01-02, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1127921, encodeId=2425112e92180, content=误差线怎么计算？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Tue Dec 28 14:52:59 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1127922, encodeId=1590112e92280, content=qPCR的结果如何处理？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:59 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
    2021-12-28 Mia

    qPCR的结果如何处理？

    1

    展开1条回复
共9条页码: 1/1页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分